Previous studies have shown that other approaches such as IFN‐A/peg‐IFN‐A,28, 29 a BCL‐2 inhibitor (venetoclax), a JAK2 inhibitor (ruxolitinib), a BTK inhibitor, a PPAR‐γ (pioglitazone),30 and a PD‐1 antibody in combination with TKI, can be applied to eliminate CML stem cells in patients with CML not achieving DMR with TKI monotherapy.31, 32. This evidence concerns the gene PPARG and chronic myelogenous leukemia, BCR-ABL1 positive.